Psygen Receives Dealer’s Licence To Become Canada’s First Dedicated Psychedelics Manufacturing Facility Jan 18, 2022
Ibogaine Addiction Treatments & MDMA Assisted-Psychotherapy: MINDCURE & The State Of Psychedelic Therapeutics… Nov 23, 2021
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder Sep 21, 2021
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research Jul 27, 2021
